Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (121-130 of 172) with videos related to

Pageof 18
Sort By:
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2018
The Science Behind Biosimilars: Entering a New Era of Biologic TherapyS Louis Bridges, Douglas W White, Angus B Worthing, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
Rheumatology (Oxford, England)|December 11, 2012
Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) databaseDaniel Schneeberger, Alan Tyndall, Jonathan Kay, et al.
NPJ Science of Learning|May 10, 2025
A new education agenda based on The International Science and Evidence Based Education AssessmentNandini Chatterjee Singh, Tal Gilead, Anya Chakraborty, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Joachim Sieper, Jürgen Braun, Jonathan Kay, et al.
Echo Research and Practice|November 5, 2017
Transthoracic echocardiography is adequate for intraprocedural guidance of transcatheter aortic valve implantationRenuka Jain, Daniel P O'Hair, Tanvir K Bajwa, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|May 22, 2018
Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media PlatformsEldin Dzubur, Carine Khalil, Christopher V Almario, et al.
Arthritis Research & Therapy|January 29, 2015
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER studyJosef S Smolen, Jonathan Kay, Mittie Doyle, et al.
Pageof 18

Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|March 11, 2016
The changing landscape of biosimilars in rheumatologyThomas Dörner, Vibeke Strand, Paul Cornes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2018
The Science Behind Biosimilars: Entering a New Era of Biologic TherapyS Louis Bridges, Douglas W White, Angus B Worthing, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
Rheumatology (Oxford, England)|December 11, 2012
Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) databaseDaniel Schneeberger, Alan Tyndall, Jonathan Kay, et al.
NPJ Science of Learning|May 10, 2025
A new education agenda based on The International Science and Evidence Based Education AssessmentNandini Chatterjee Singh, Tal Gilead, Anya Chakraborty, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Joachim Sieper, Jürgen Braun, Jonathan Kay, et al.
Echo Research and Practice|November 5, 2017
Transthoracic echocardiography is adequate for intraprocedural guidance of transcatheter aortic valve implantationRenuka Jain, Daniel P O'Hair, Tanvir K Bajwa, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|May 22, 2018
Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media PlatformsEldin Dzubur, Carine Khalil, Christopher V Almario, et al.
Arthritis Research & Therapy|January 29, 2015
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER studyJosef S Smolen, Jonathan Kay, Mittie Doyle, et al.
Pageof 18